Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 4/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25232243 | 0.93 | KDM1A (0.41) | KDM1AUSP30USP2SMN1; SMN2PDE4A | |
| SCHEMBL21408126 | 0.93 | KDM1A (0.41) | KDM1AUSP30USP2SMN1; SMN2PDE4A | |
| SCHEMBL25281708 | 0.92 | KDM1A (0.40) | KDM1AUSP30USP2SMN1; SMN2PDE4A | |
| SCHEMBL17113437 | 0.89 | KDM1A (0.39) | KDM1AUSP30USP2SMN1; SMN2PDE4A | |
| SCHEMBL19839783 | 0.87 | KDM1A (0.42) | KDM1AUSP30USP2SMN1; SMN2PDE4A | |
| SCHEMBL29348862 | 0.87 | USP2 (0.41) | KDM1AUSP30USP2SMN1; SMN2PDE4A | |
| SCHEMBL8018479 | 0.83 | USP30 (0.46) | USP30USP2SMN1; SMN2HRH3KDM4E | |
| SCHEMBL479856 | 0.83 | KDM1A (0.43) | KDM1AUSP30USP2SMN1; SMN2PDE4A | |
| SCHEMBL3733424 | 0.81 | KDM1A (0.42) | KDM1AUSP30USP2SMN1; SMN2PDE4A | |
| SCHEMBL27192628 | 0.81 | KDM1A (0.42) | KDM1AUSP30USP2SMN1; SMN2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-3577118-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-117677614-A | Heterocyclic compound with AKT kinase inhibition activity, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-116514817-A | Heterocyclic compound with AKT kinase inhibition activity, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2023109540-A1 | HETEROCYCLIC COMPOUND WITH AKT KINASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-10442804-B2 | Compounds for the treatment of hepatitis B virus infection | GILEAD SCIENCES, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180251460-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2018-09-06 | — | — | US | disclosed |
| WO-2018144605-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251460-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | HAVCR2, PYGL, OAT | KDM1A 4552/4885USP30 3238/4885USP2 2474/4885 |
| US-10442804-B2 | Compounds for the treatment of hepatitis B virus infection | HAVCR2, PYGL, OAT | KDM1A 4552/4885USP30 3238/4885USP2 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.